Showing results (191-200 of 432) with videos related to
Sort By:
Pageof 44
AIDS Research and Human Retroviruses|August 2, 2008
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot studyElena Ferrer, Jose Maria Gatell, Pochita Sanchez, et al.The Journal of Antimicrobial Chemotherapy|January 14, 2014
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study GroupAdrian Curran, Polyana Monteiro, Pere Domingo, et al.Cancer|July 28, 2010
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignanciesJoanne Reekie, Csaba Kosa, Frederik Engsig, et al.Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|September 6, 2016
Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different componentsJosep M Llibre, Elisa de Lazzari, Jean-Michel Molina, et al.Journal of Medical Case Reports|August 30, 2008
Impaired expression of mitochondrial and adipogenic genes in adipose tissue from a patient with acquired partial lipodystrophy (Barraquer-Simons syndrome): a case reportJordi P Guallar, Ricardo Rojas-Garcia, Elena Garcia-Arumi, et al.Frontiers in Public Health|October 11, 2021
Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional StudyJuan Antonio Arroyo-Díaz, Josep Julve, Bogdan Vlacho, et al.AIDS (London, England)|April 15, 2015
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antiviralsDaniel Grint, Lars Peters, Juergen K Rockstroh, et al.AIDS (London, England)|November 25, 2011
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudyAdrian Curran, Esteban Martinez, Maria Saumoy, et al.The Journal of Antimicrobial Chemotherapy|May 9, 2012
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteersJavier A Estévez, José Moltó, Laura Tuneu, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2018
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 TrialAdriana Ammassari, Wolfgang Stöhr, Andrea Antinori, et al.Pageof 44